Literature DB >> 16238923

Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.

Stephen Lazarou1, Abraham Morgentaler.   

Abstract

Hypogonadism (low serum testosterone) is commonly associated with erectile dysfunction (ED). However, many urologists may lack appreciation of the relative merits of treating hypogonadism compared with oral phosphodiesterase inhibitors for sexual dysfunction. Testosterone-replacement therapy (TRT) may be the best treatment for men with ED when the presentation includes diminished libido or other sexual symptoms or when non-sexual symptoms such as depressed mood, decreased sense of vitality, and increased fatigue also exist. The health benefits of TRT also include improvements in body composition, bone density, cognition, and sense of well-being. Thus, there may be good reasons to use TRT as first-line therapy for the man with ED. Concerns regarding prostatic and cardiovascular risks of TRT have not been supported by the literature. Nevertheless, men receiving TRT must be monitored at regular intervals with digital rectal examination and blood testing for prostate-specific antigen. Hematocrit or hemoglobin also should be obtained regularly due to the risk of erythrocytosis. Awareness of the benefits of TRT in the man with ED may improve clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238923     DOI: 10.1007/s11934-005-0044-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  37 in total

Review 1.  Erectile dysfunction.

Authors:  T F Lue
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

2.  Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial.

Authors:  Wayne J G Hellstrom; Marc Gittelman; Gary Karlin; Thomas Segerson; Marc Thibonnier; Terry Taylor; Harin Padma-Nathan
Journal:  J Androl       Date:  2002 Nov-Dec

Review 3.  Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

Authors:  Shalender Bhasin; Atam B Singh; Ricky Phong Mac; Ballentine Carter; Martin I Lee; Glenn R Cunningham
Journal:  J Androl       Date:  2003 May-Jun

4.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

5.  Occult prostate cancer in men with low serum testosterone levels.

Authors:  A Morgentaler; C O Bruning; W C DeWolf
Journal:  JAMA       Date:  1996-12-18       Impact factor: 56.272

6.  Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

Authors:  R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

7.  Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease.

Authors:  C M Webb; J G McNeill; C S Hayward; D de Zeigler; P Collins
Journal:  Circulation       Date:  1999-10-19       Impact factor: 29.690

8.  Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

Authors:  C Wang; R S Swerdloff; A Iranmanesh; A Dobs; P J Snyder; G Cunningham; A M Matsumoto; T Weber; N Berman
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

9.  Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?

Authors:  Alexander Greenstein; Nicola J Mabjeesh; Mario Sofer; Issac Kaver; Haim Matzkin; Juza Chen
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

10.  Longitudinal evaluation of serum androgen levels in men with and without prostate cancer.

Authors:  H B Carter; J D Pearson; E J Metter; D W Chan; R Andres; J L Fozard; W Rosner; P C Walsh
Journal:  Prostate       Date:  1995-07       Impact factor: 4.104

View more
  2 in total

1.  Risk factors for idiopathic intracranial hypertension in men: a case-control study.

Authors:  J Alexander Fraser; Beau B Bruce; Janet Rucker; Lisa-Ann Fraser; Edward J Atkins; Nancy J Newman; Valérie Biousse
Journal:  J Neurol Sci       Date:  2009-11-30       Impact factor: 3.181

2.  Testosterone and vascular function in aging.

Authors:  Rhéure A M Lopes; Karla B Neves; Fernando S Carneiro; Rita C Tostes
Journal:  Front Physiol       Date:  2012-04-10       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.